Wells Fargo Says These 2 Stocks Are Worth Buying Now — Here’s Why
For much of the past several years, some of the market’s biggest gains have come from a relatively narrow group of mega-cap tech stocks. That pictu...
Ptc Therapeutics Inc. (PTCT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Hood River Capital Management David Swank | 1,738,613 | $141,818,662 | +5% | 1.03% |
| 2. | D E Shaw D. E. Shaw | 1,548,919 | $126,345,323 | -6% | 0.06% |
| 3. | Tang Capital Management Kevin C. Tang | 1,500,000 | $122,355,000 | 5.56% | |
| 4. | Driehaus Capital Richard Driehaus | 1,440,107 | $117,469,528 | +42% | 0.68% |
| 5. | Leucadia National Ian Cumming And Joseph Steinberg | 1,357,042 | $110,693,916 | +1% | 0.73% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.81 | 7,700 | $198,736.23 | 33,700 | 2023-12-12 | Filing | |
| $32.48 | 10,000 | $324,846.00 | 100,066 | 2020-03-16 | Filing | |
| $30.20 | 66,225 | $1,999,995.00 | 1,386,594 | 2019-01-25 | Filing | |
| $13.49 | 25,000 | $337,230.00 | 25,000 | 2017-05-23 | Filing | |
| $6.23 | 2,000 | $12,460.00 | 5,125 | 2016-03-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $68.45 | 376 | $25,737.20 | 1,296,594 | 2026-09-17 | Filing | |
| $67.83 | 9,624 | $652,795.92 | 1,296,970 | 2026-09-17 | Filing | |
| $67.35 | 7,006 | $471,854.10 | 1,306,594 | 2026-09-16 | Filing | |
| $66.58 | 2,994 | $199,340.52 | 1,313,600 | 2026-09-16 | Filing | |
| $67.34 | 10,000 | $673,400.00 | 1,316,594 | 2026-09-10 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,964,554 | $1,139,088,671 | 0.02% | |
| 2. | 7,746,415 | $631,875,072 | 5.39% | |
| 3. | 7,236,402 | $590,181,512 | 0.24% | |
| 4. | 4,928,111 | $401,986,014 | 0.02% | |
| 5. | 4,598,952 | $375,136,515 | 0.01% |
News See All
Measuring the Beat: 57 Stocks Surpassing Earnings Expectations
Academic research has consistently found that corporate earnings surprises cluster around small positive values, rather than large outperformance.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2026 Earnings Call Transcript
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2026 Earnings Call Transcript May 8, 2026 Operator: Ladies and gentlemen, thank you for standing by.
PTC Therapeutics (PTCT) Reports Positive Huntington’s Disease Trial Results
PTC Therapeutics, Inc. (NASDAQ:PTCT) ranks among the most profitable biotech stocks to buy now. On April 28, PTC Therapeutics, Inc.
10 Most Profitable Biotech Stocks to Buy Now
In this article, we will take a look at the 10 Most Profitable Biotech Stocks to Buy Now.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2025 Earnings Call Transcript
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2025 Earnings Call Transcript February 20, 2026 Operator: Ladies and gentlemen, thank you for standing by.
Morgan Stanley Is Bullish on PTC Therapeutics, Inc. (PTCT) as Small-Cap Biotech Outlook Improves
We recently compiled a list of the 15 High Growth Mid-Cap Stocks to Buy. PTC Therapeutics, Inc. is among the best high growth stocks.
15 High Growth Mid-Cap Stocks to Buy
In this article, we will be taking a look at the 15 High Growth Mid-cap Stocks to Buy.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q3 2025 Earnings Call Transcript
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q3 2025 Earnings Call Transcript November 5, 2025 Operator: Ladies and gentlemen, thank you for standing by.
Bank of America Securities Lifts PT on PTC Therapeutics (PTCT) to $87 From $76
PTC Therapeutics, Inc. (NASDAQ:PTCT) is one of the most profitable biotech stocks to buy.
Hedge Fund Resource Center